scholarly journals Developmental course of non-medical use of prescription drugs from adolescence to adulthood in the United States: national longitudinal data

Addiction ◽  
2016 ◽  
Vol 111 (12) ◽  
pp. 2166-2176 ◽  
Author(s):  
Sean Esteban McCabe ◽  
Deborah D. Kloska ◽  
Philip Veliz ◽  
Justin Jager ◽  
John E. Schulenberg
Keyword(s):  
United States ◽  
Longitudinal Data ◽  
Prescription Drugs ◽  
The United States ◽  
Developmental Course

The Nonmedical Use of Prescription Drugs in the United States

1993 ◽  
Author(s):  
Edgar H. Adams ◽  
◽  
Andrea N. Kopstein
Keyword(s):  
United States ◽  
Prescription Drugs ◽  
The United States ◽  
Nonmedical Use

Fake Pharmaceuticals: How They and Relevant Legislation or Lack Thereof Contribute to Consistently High and Increasing Drug Prices

2003 ◽  
Vol 29 (4) ◽  
pp. 525-542
Author(s):  
Merri C. Moken
Keyword(s):  
United States ◽  
Prescription Drugs ◽  
The United States ◽  
Pharmaceutical Products ◽  
New Drugs ◽  
Pharmaceutical Companies ◽  
Brand Name ◽  
Potential Factors ◽  
Counterfeit Pharmaceuticals ◽  
New Applications

The use of pharmaceutical products in the United States has increased more than the use of any other health resource from 1960 to 1990. In excess of 9,600 drugs were on the market in 1984, and the Food and Drug Administration (“FDA”) approves approximately 30 new drugs and countless new applications for alterations of already existing drugs each year. In 2001, the $300 billion pharmaceutical industry sold $154 billion worth of prescription drugs in the United States alone, nearly doubling its $78.9 billion in sales in 1997. With such a rapid increase in market domination and expenditures, the U.S. government and many hospitals have focused their attention on the sales and pricing practices of pharmaceutical companies, as well as other potential factors contributing to these escalating prices. One such cause of the steadily increasing prices of brand name pharmaceuticals is the sale of fake or counterfeit pharmaceuticals (also called “look-alike” drugs).

The Epidemiology of Drug Promotion

1977 ◽  
Vol 7 (2) ◽  
pp. 157-166 ◽  
Author(s):  
Milton Silverman
Keyword(s):  
United States ◽  
Latin America ◽  
Latin American ◽  
Prescription Drugs ◽  
The United States ◽  
Corporate Ethics ◽  
Social Responsibilities ◽  
The One ◽  
Global Company ◽  
Latin American Countries

A survey was conducted on the promotion of 28 prescription drugs in the form of 40 different products marketed in the United States and Latin America by 23 multinational pharmaceutical companies. Striking differences were found in the manner in which the identical drug, marketed by the identical company or its foreign affiliate, was described to physicians in the United States and to physicians in Latin America. In the United States, the listed indications were usually few in number, while the contraindications, warnings, and potential adverse reactions were given in extensive detail. In Latin America, the listed indications were far more numerous, while the hazards were usually minimized, glossed over, or totally ignored. The differences were not simply between the United States on the one hand and all the Latin American countries on the other. There were substantial differences within Latin America, with the same global company telling one story in Mexico, another in Central America, a third in Ecuador and Colombia, and yet another in Brazil. The companies have sought to defend these practices by contending that they are not breaking any Latin American laws. In some countries, however, such promotion is in clear violation of the law. The corporate ethics and social responsibilities concerned here call for examination and action.

scholarly journals Controversial advertising of medicines. A comparison between Poland and the United States

2018 ◽  
Vol 21 (5) ◽  
pp. 67-79
Author(s):  
Marta Makowska
Keyword(s):  
United States ◽  
Prescription Drugs ◽  
The United States ◽  
The European Union ◽  
Negative Consequences ◽  
Direct To Consumer ◽  
Law And Ethics ◽  
The Us ◽  
The Law ◽  
Direct To Consumer Advertising

For many years, the subject of aggressive marketing campaigns conducted by pharmaceutical companies has been raised in Poland. Drug ads are everywhere, on television, the radio, magazines and on the Internet. Therefore, it is extremely important is to ensure both their legal and ethical dimension. This article will present the differences between direct-to-consumer advertising of medicines in Poland and in the US. The dissimilarities result mainly from differences in legislation. In Poland, the law is much stricter than in the US. For example, in the United States companies are allowed to advertise prescription drugs directly to patients. In the whole of the European Union, and thus in Poland, it is strictly prohibited. The article will also present other regulations existing in Poland and in the United States and it will compare them. It will offer examples of violations of the law and ethics in the advertising of medicine in both countries. Lastly, it will briefly outline the negative consequences of unacceptable pharmaceutical marketing.

scholarly journals What Happens after an Abortion Denial? A Review of Results from the Turnaway Study

2020 ◽  
Vol 110 ◽  
pp. 226-230
Author(s):  
Sarah Miller ◽  
Laura R. Wherry ◽  
Diana Greene Foster
Keyword(s):  
United States ◽  
Human Capital ◽  
Longitudinal Data ◽  
Administrative Data ◽  
The United States ◽  
Opportunities To Learn ◽  
Study Team

We provide a brief overview of the Turnaway Study, the first study to collect longitudinal data on individual women who received versus were denied a wanted abortion in the United States. The study team collected data on nearly 1,000 women seeking an abortion from 30 facilities around the country and followed them for 5 years. We discuss some of the main findings from the study related to the health, labor, and human capital outcomes of the women who were denied abortions and gave birth. We conclude by describing future opportunities to learn from the study with new linkages to administrative data.

An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countries

Health Policy ◽  
2018 ◽  
Vol 122 (9) ◽  
pp. 1012-1017 ◽  
Author(s):  
Steven G. Morgan ◽  
Chester B. Good ◽  
Christine Leopold ◽  
Anna Kaltenboeck ◽  
Peter B. Bach ◽  
...  
Keyword(s):  
United States ◽  
Primary Care ◽  
Prescription Drugs ◽  
The United States
Sign in / Sign up

Export Citation Format

Share Document